Результати пошуку - Birgit Bossenmaier
- Показ 1 - 14 результатів із 14
-
1
Acquired Resistance to Antibody-Drug Conjugates за авторством Denis M. Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen, Gerhard Niederfellner
Опубліковано 2019Revisão -
2
-
3
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models за авторством Werner Scheuer, Thomas Friess, Helmut Burtscher, Birgit Bossenmaier, Josef Endl, Max Hasmann
Опубліковано 2009Artigo -
4
Differential activities of protein tyrosine phosphatases in intact cells. за авторством Reiner Lammers, Birgit Bossenmaier, D E Cool, N. K. Tonks, Joseph Schlessinger, E H Fischer, A. Ullrich
Опубліковано 1993Artigo -
5
Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. за авторством G Kroder, Birgit Bossenmaier, Monika Kellerer, Edison Capp, B Stoyanov, A Mühlhöfer, Lucia Berti, Hiroyoshi Horikoshi, A. Ullrich, Hans-Ulrich Häring
Опубліковано 1996Artigo -
6
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer за авторством Denis M. Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Maja Weisser, Birgit Bossenmaier
Опубліковано 2017Artigo -
7
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity за авторством Yasmin Leshem, James O'Brien, Xiufen Liu, Tapan K. Bera, Masaki Terabe, Jay A. Berzofsky, Birgit Bossenmaier, Gerhard Niederfellner, Chin‐Hsien Tai, Yoram Reiter, Ira Pastan
Опубліковано 2017Artigo -
8
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation за авторством Christian Mirschberger, Christian Schiller, Michael Schräml, Nikolaos Dimoudis, Thomas Friess, Christian A. Gerdes, Ulrike Reiff, Valeria Lifke, Gabriele Hoelzlwimmer, Irene Kolm, Karl‐Peter Hopfner, Gerhard Niederfellner, Birgit Bossenmaier
Опубліковано 2013Artigo -
9
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab за авторством Christian A. Gerdes, Valeria Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine M. Lang, Michaela Roemmele, Ekkehard Moessner, Olivier Freytag, Thomas Friess, Carola H. Ries, Birgit Bossenmaier, Hans Joachim Mueller, Pablo Umaña
Опубліковано 2012Artigo -
10
ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody<sup>89</sup>Zr-RG7116 за авторством Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub–de Hooge, K. Abiraj, Carolien P. Schröder, Linda Pot, Birgit Bossenmaier, Marlène Thomas, Gabriele Hölzlwimmer, Thomas Friess, Jos G.W. Kosterink, Elisabeth G.E. de Vries
Опубліковано 2014Artigo -
11
Characterization of a re‐engineered, mesothelin‐targeted<i>Pseudomonas</i>exotoxin fusion protein for lung cancer therapy за авторством Frieder Bauss, Martin Lechmann, Ben‐Fillippo Krippendorff, Roland F. Staack, Frank Herting, Matthias Festag, Sabine Imhof-Jung, Friederike Hesse, Marc Pompiati, Gwendlyn Kollmorgen, Rita da Silva Mateus Seidl, Birgit Bossenmaier, Wilma Lau, Christian Schantz, Jan Olaf Stracke, Ulrich Brinkmann, Masanori Onda, Ira Pastan, Klaus Bosslet, Gerhard Niederfellner
Опубліковано 2016Artigo -
12
The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner за авторством Janet K. Peper-Gabriel, Marina Pavlidou, Lucia Pattarini, Aizea Morales‐Kastresana, Thomas J. Jaquin, Catherine Gallou, Eva-Maria Hansbauer, Marleen Richter, Hélène Lelièvre, Alix Scholer‐Dahirel, Birgit Bossenmaier, Celine Sancerne, Matthieu Rivière, Maximilien Grandclaudon, Markus Zettl, Rachida S. Bel Aiba, Christine Rothe, Véronique Blanc, Shane A. Olwill
Опубліковано 2022Artigo -
13
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors за авторством Didier Meulendijks, Wolfgang Jacob, Maria Martinez‐García, Álvaro Taus, Martijn P. Lolkema, Emile E. Voest, Marlies H.G. Langenberg, Tania Fleitas, Andrés Cervantes, Maja J. De Jonge, Stefan Sleijfer, Morten Mau‐Sørensen, Marlène Thomas, Maurizio Ceppi, Georgina Meneses‐Lorente, Ian James, Céline Adessi, Francesca Michielin, K. Abiraj, Birgit Bossenmaier, Jan H.M. Schellens, Maja Weisser, Ulrik Lassen
Опубліковано 2015Artigo -
14
Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer за авторством Denis M. Collins, Stephen F. Madden, Nicola Gaynor, Dalal AlSultan, Marion Le Gal, Alex J. Eustace, Kathy Gately, Clare Hughes, Anthony M. Davies, Thamir Mahgoub, Jo Ballot, Sinéad Toomey, Darran P. O’Connor, William M. Gallagher, Frankie A. Holmes, Virginia Espina, Lance A. Liotta, Bryan T. Hennessy, Kenneth J. O’Byrne, Max Hasmann, Birgit Bossenmaier, Norma O’Donovan, John Crown
Опубліковано 2020Artigo
Інструменти для пошуку:
Пов'язані теми
Biology
Cancer research
Antibody
Biochemistry
Immunology
Medicine
Monoclonal antibody
Internal medicine
Cancer
In vitro
Receptor
Chemistry
Pharmacology
Biotechnology
Cell biology
Endocrinology
In vivo
Antigen
Breast cancer
Cytotoxicity
Gene
Immune system
Phosphorylation
Tyrosine kinase
Tyrosine phosphorylation
Autophosphorylation
CD8
Cytotoxic T cell
Humanized antibody
Immunotoxin